Article Impact Level: HIGH Data Quality: STRONG Summary of Journal of the American College of Cardiology, 83(1), 47–59. https://doi.org/10.1016/j.jacc.2023.10.029 Dr. Alessio Alogna et al.
Points
- The study aimed to assess the tolerability and efficacy of LungToHeartNIM, an inhalable delivery system, for targeting a mimetic peptide in a porcine model of heart failure with reduced ejection fraction (HFrEF).
- Using a porcine model of HFrEF induced by tachypacing, inhaling a dry powder containing MP-loaded calcium phosphate nanoparticles led to significant restoration of systolic function, reversal of cardiac remodeling, and reduction of pulmonary congestion.
- The treatment demonstrated an absolute increase in left ventricular ejection fraction (LVEF) over the treatment period, indicating a positive impact on cardiac function.
- The LungToHeartNIM delivery system was well tolerated, with no reported adverse events, highlighting its safety profile in the porcine model.
- The findings suggest that LungToHeartNIM, with the MP-loaded calcium phosphate nanoparticles, holds promise as a potential game-changing treatment for HFrEF patients, addressing the critical need for disease-modifying drugs in heart failure management.
Summary
The study aimed to evaluate the tolerability and efficacy of an inhalable lung-to-heart nano-in-micro technology (LungToHeartNIM) for cardiac-specific targeting of a mimetic peptide (MP) in a porcine model of heart failure with reduced ejection fraction (HFrEF). The authors sought to address the unmet need for disease-modifying drugs in heart failure patients by assessing the potential of this novel delivery system for a first-in-class mimetic peptide designed to modulate impaired L-type calcium channel (LTCC) trafficking.
Using a clinically relevant porcine model of HFrEF induced by tachypacing, the study demonstrated that inhalation of a dry powder composed of MP-loaded calcium phosphate nanoparticles embedded in mannitol-based microparticles (dpCaP-MP) led to a significant restoration of systolic function, as evidenced by an absolute increase in left ventricular ejection fraction (LVEF) over the treatment period. This treatment also resulted in reversing cardiac remodeling and reducing pulmonary congestion. Notably, the LungToHeartNIM delivery system was well tolerated, with no reported adverse events, indicating its safety profile.
The study’s findings suggest that the LungToHeartNIM technology, in conjunction with the MP-loaded calcium phosphate nanoparticles, holds promise as a game-changing treatment for HFrEF patients. The successful restoration of systolic function and reversal of cardiac remodeling, along with the absence of adverse events, underscores the potential of this innovative approach for delivering therapeutic peptides to the diseased heart, addressing a critical need in heart failure management.
Link to the article: https://www.sciencedirect.com/science/article/pii/S073510972307986X
References Alogna, A., Berboth, L., Faragli, A., Ötvös, J., Lo Muzio, F. P., Di Mauro, V., Modica, J., Quarta, E., Semmler, L., Deißler, P. M., Berger, Y. W., Tran, K. L., De Marchi, B., Longinotti-Buitoni, G., Degli Esposti, L., Guillot, E., Bazile, D., Iafisco, M., Dotti, A., … Catalucci, D. (2024). Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure. Journal of the American College of Cardiology, 83(1), 47–59. https://doi.org/10.1016/j.jacc.2023.10.029
